Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 691 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Headache Clear all
Active, not recruiting Phase 4 Interventional

Nerivio Efficacy Under High-Frequency Use

NCT07336056
View directory record Official record
Conditions
Migraine
Interventions
Nerivio (REN device)
Device
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 12, 2026, 1:18 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

NCT03576820
View directory record Official record
Conditions
Migraine
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
10 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 12, 2026, 1:18 PM EDT
Not yet recruiting Not applicable Interventional

Can a Specific OMT Protocol Influence Patient Pain and Associated Analgesia Use for Primary Headache Disorders?

NCT06546462
View directory record Official record
Conditions
Headache Disorders, Headache, Analgesia, Opioid Use, Osteopathy
Interventions
Osteopathic Manipulative Treatment (OMT), Sham Light touch arm
Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

NCT00792636
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

NCT03927144
View directory record Official record
Conditions
Episodic Migraine
Interventions
AMG334, Oral Prophylactic
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 12, 2026, 1:18 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 12, 2026, 1:18 PM EDT
Not listed Phase 1Phase 2 Interventional

Status Migrainosus - Differentiating Between Responders and Non-responders

NCT03066544
View directory record Official record
Conditions
Migraine
Interventions
Bupivacaine, Naratriptan Pill, Dexamethasone, Ketorolac
Drug
Lead sponsor
Hartford HealthCare
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Wethersfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 12, 2026, 1:18 PM EDT
Terminated Phase 2 Interventional Results available

Melatonin for Adolescent Migraine Prevention Study

NCT03150797
View directory record Official record
Conditions
Migraine
Interventions
Melatonin, Placebo oral capsule
Drug
Lead sponsor
Amy Gelfand
Other
Eligibility
10 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack

NCT00330850
View directory record Official record
Conditions
Migraine, Photophobia, Phonophobia
Interventions
PRO-513
Drug
Lead sponsor
ProEthic Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Fairfield, Connecticut • Stamford, Connecticut • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2007 · Synced Oct 12, 2026, 1:18 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07645924
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Loxapine in Migraine (in Clinic)

NCT00489476
View directory record Official record
Conditions
Migraine
Interventions
Staccato Loxapine, Staccato Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 12, 2026, 1:18 PM EDT
Not listed Phase 3 Interventional

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

NCT02779959
View directory record Official record
Conditions
Migraine Disorders
Interventions
Prochlorperazine
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 12, 2026, 1:18 PM EDT
Recruiting Not applicable Interventional

Responding With Evidence and Access for Childhood Headaches

NCT05889624
View directory record Official record
Conditions
Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
CBT, Amitriptyline
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

NCT02638103
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 12, 2026, 1:18 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

NCT02132429
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Fresno, California • Newport Beach, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605
View directory record Official record
Conditions
Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
38
States / cities
Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

Open-trial on the Prevention of Chronic Migraines With the CEFALY Device

NCT02342743
View directory record Official record
Conditions
Migraine
Interventions
CEFALY
Device
Lead sponsor
Cefaly Technology
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

NCT00792103
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 12, 2026, 1:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

NCT02758990
View directory record Official record
Conditions
Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds, Dyspnea, Headache, Migraine Disorders, Arthritis, Arthralgia, Anxiety, Sleep Initiation and Maintenance Disorders, Sleep Deprivation
Interventions
Vitamin A, Vitamin B6, Vitamin C, Nicotinamide, Vitamin D3, Vitamin E, Broccoli, Spinach, Caffeine, Coffee, Axon Eyewear, Chocolate
Dietary Supplement · Other · Device
Lead sponsor
Verifomics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

NCT03275922
View directory record Official record
Conditions
Migraine
Interventions
Placebo ZNS, ZNS
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

NCT02609945
View directory record Official record
Conditions
Migraine
Interventions
zolmitriptan, CVT-427 (zolmitriptan inhalation powder),
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 12, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

A Study of Home-Delivered Neurostimulation for Migraine

NCT03874351
View directory record Official record
Conditions
Migraine Disorders
Interventions
non-invasive transcranial direct current stimulation (tDCS)
Device
Lead sponsor
MJHS Institute for Innovation in Palliative Care
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 12, 2026, 1:18 PM EDT